Investors
Interested in Fasikl?
Explore What Sets Us Apart
Fasikl is leading the way in AI and neurotechnology innovation. We developed the Felix™ NeuroAI™ Wristband, the first and only FDA-approved AI therapeutic for the treatment of essential tremor.
The Felix™ NeuroAI™ Wristband was validated in a gold-standard, double-blind, randomized, sham-controlled clinical trial. The treatment group demonstrated highly significant improvements compared to the placebo group.
Fasikl’s proprietary technologies and intellectual property support a scalable product pipeline aimed at addressing a broad range of neurological and movement disorders.
Fasikl is deeply committed to healthcare innovation with a focused mission to treat disease. Every solution we develop is designed with efficacy, safety, and convenience in mind to improve patient outcomes and quality of life.
Fasikl is the only company currently capable of recording neural signals from human peripheral nerves at single-fiber resolution, while simultaneously delivering electrical stimulation. These groundbreaking capabilities enable the creation of next-generation AI models that drive transformative neuromodulation therapies.
Fasikl is pioneering a nerve–computer interface tested in human amputees, enabling near-natural, high-degree-of-freedom control of robotic hands. This interface supports intuitive, voluntary movement—where the user thinks, and the hand responds.
Fasikl is dedicated to advancing AI therapeutics and delivering treatment solutions that are better. Our long-term mission is to explore the frontier of body–AI communication, supported by over 20 years of deep scientific expertise, proprietary technologies, and ongoing innovation.
Interested in discussing investment opportunities?
Please contact Dr. Zhi Yang, CEO of Fasikl.
